675112-67-1

Basic information

• Product Name: N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE
• Synonyms: N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE;Tert-butyl4,4-difluorocyclohexylcarbaMate;tert-butyl N-(4,4-difluorocyclohexyl)carbamate
• CAS NO: 675112-67-1
• Molecular Formula: C₁₁H₁₉F₂NO₂
• Molecular Weight: 235.27
• Mol File: 675112-67-1.mol

Chemical Properties

• Melting Point: 119-122 °C
• Boiling Point: 293.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.46±0.40(Predicted)
• CAS DataBase Reference: N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE(675112-67-1)
• EPA Substance Registry System: N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE(675112-67-1)

Safety Data

• Hazardous Substances Data: 675112-67-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE is used as a protecting agent for amines in organic synthesis processes. The BOC group helps prevent unwanted reactions, allowing for selective reactions to occur at other sites on the molecule.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE is used as an intermediate compound in the synthesis of various drug molecules. Its unique structure, including the cyclohexyl ring and fluorine atoms, may contribute to the development of new therapeutic agents with specific properties.
Used in Chemical Research:
N-T-BOC-4,4-DIFLUOROCYCLOHEXYLAMINE is employed as a research tool in chemical laboratories, where its reactivity and properties are studied to understand its potential applications in various chemical processes and reactions. This can lead to the discovery of new synthetic pathways and the development of novel compounds with specific functions.

Upstream product

• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 675112-70-6 4,4-difluorocyclohexylamine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6850-65-3 p-hydroxycyclohexylamine 
• 224309-64-2 tert-butyl N-(4-hydroxycyclohexyl)carbamate 
• 675112-69-3 tert-butyl (4-fluorocyclohex-3-en-1-yl)carbamate 

Downstream Products

• 675112-70-6 4,4-difluorocyclohexylamine hydrochloride 
• 675112-72-8 4-fluoro-3-cyclohexen-1-amine 
• 458566-84-2 4,4-difluorocyclohexan-1-amine 
• 790254-37-4 4, 4-difluorocyclohexanamine tosic salt 
• 919836-32-1 tert-butyl (4,4-difluorocyclohexyl)methylcarbamate 
• 1448309-95-2 N-(4,4-difluorocyclohexyl)formamide 
• 1000698-98-5 1,1-difluoro-4-isocyanocyclohexane 

Relevant articles and documents

Iridinesulfonamide compound and use method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Aminodifluorosulfinium salts: Selective fluorination reagents with enhanced thermal stability and ease of handling

Diethylaminodifluorosulfinium tetrafluoroborate (XtalFluor-E) and morpholinodifluorosulfinium tetrafluoroborate (XtalFluor-M) are crystalline fluorinating agents that are more easily handled and significantly more stable than Deoxo-Fluor, DAST, and their analogues. These reagents can be prepared in a safer and more cost-efficient manner by avoiding the laborious and hazardous distillation of dialkylaminosulfur trifluorides. Unlike DAST, Deoxo-Fluor, and Fluolead, XtalFluor reagents do not generate highly corrosive free-HF and therefore can be used in standard borosilicate vessels. When used in conjunction with promoters such as Et3N3HF, Et3N2HF, or DBU, XtalFluor reagents effectively convert alcohols to alkyl fluorides and carbonyls to gem-difluorides. These reagents are typically more selective than DAST and Deoxo-Fluor and exhibit superior performance by providing significantly less elimination side products.

Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors

The disclosure relates to compounds of formula (I): wherein R1-R5, A and Y are as defined in the disclosure, to compositions comprising said compounds, and to processes for making and methods of using the same.